Re: Od 17. května do školy všichni včetně středoškoláků

Jenže vědecké podklady pro PLOŠNOU dlouhodobou imunitu taky nesvědčí...
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00025-2/fulltext
SHRNU: Jak u koho, u někoho ano, u jiného ne, předpovídat vývoj u toho kterého jednotlivce není jak.

12% nevytvořilo nic, 27% bylo do 6 měsíců negativních, 28% bylo v 6 měsících ještě pozitivních na protilátky, ale klesalo to, 32% to zůstalo bez poklesu a u 2% to rostlo.

We approached 517 patients for participation in the study, of whom 288 consented for outpatient follow-up and collection of serial blood samples. 164 patients were followed up and had adequate blood samples collected for analysis, with a total of 546 serum samples collected, including 128 blood samples taken up to 180 days post-symptom onset. We identified five distinctive patterns of neutralising antibody dynamics as follows: negative, individuals who did not, at our intervals of sampling, develop neutralising antibodies at the 30% inhibition level (19 [12%] of 164 patients); rapid waning, individuals who had varying levels of neutralising antibodies from around 20 days after symptom onset, but seroreverted in less than 180 days (44 [27%] of 164 patients); slow waning, individuals who remained neutralising antibody-positive at 180 days post-symptom onset (46 [28%] of 164 patients); persistent, although with varying peak neutralising antibody levels, these individuals had minimal neutralising antibody decay (52 [32%] of 164 patients); and delayed response, a small group that showed an unexpected increase of neutralising antibodies during late convalescence (at 90 or 180 days after symptom onset; three [2%] of 164 patients). Persistence of neutralising antibodies was associated with disease severity and sustained level of pro-inflammatory cytokines, chemokines, and growth factors. By contrast, T-cell responses were similar among the different neutralising antibody dynamics groups. On the basis of the different decay dynamics, we established a prediction algorithm that revealed a wide range of neutralising antibody longevity, varying from around 40 days to many decades.